Optimal management of endometrial hyperplasia

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 15, Issue 3, 2001, Pages 393-405

  Marsden, Donald E ^a   Hacker, Neville F ^a  

^a ROYAL HOSPITAL FOR WOMEN   (Australia)

Author keywords

Danazol; Endometrial ablation; Endometrial cancer; Endometrial carcinoma; Hysterectomy; Progestins

Indexed keywords

DANAZOL; GESTAGEN; GONADORELIN DERIVATIVE; LEVONORGESTREL; MEDROXYPROGESTERONE; MEGESTROL ACETATE; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; TRIPTORELIN;

BODY WEIGHT DISORDER; CANCER DIAGNOSIS; CANCER GROWTH; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CURETTAGE; DISEASE CLASSIFICATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG COST; DRUG FORMULATION; DRUG MEGADOSE; DRUG RELEASE; EDEMA; EMBOLISM; ENDOMETRIOID CARCINOMA; ENDOMETRIUM ABLATION; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; HEADACHE; HEALTH CARE QUALITY; HUMAN; HYPERTENSION; MALIGNANT NEOPLASTIC DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; THROMBOPHLEBITIS; TRANSVAGINAL ECHOGRAPHY; VAGINAL HYSTERECTOMY; VEIN THROMBOSIS;

EID: 0034929382     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1053/beog.2000.0184     Document Type: Article

References (55)

1. Endometrial hyperplasia and carcinoma of the body of the uterus
2. Relation of endometrial hyperplasia to adenocarcinoma of the uterus
3. Precursors of corpus carcinoma. Estrogens and adenomatous hyperplasia
4. Precursors of corpus cancer. IV. Adenomatous hyperplasia as stage 0 carcinoma of the endometrium
5. Genesis of endometrial carcinoma. I. Study of prior biopsies
6. Carcinoma in situ of the endometrium
7. The premalignant phase of endometrial carcinoma
8. The significance of atypical endometrial hyperplasia
9. Precancerous lesions of the endometrium
10. Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium - Further observations
11. Endometrial hyperplasias, precursors of endometrial carcinoma
12. Endometrial hyperplasia and carcinoma in situ
13. Glandular intraepithelial neoplasia (GIN) - A unifying concept of the precursors of endometrial adenocarcinoma
14. The endometrial hyperplasias
15. Precancerous lesions of the endometrium
16. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well differentiated carcinoma
17. The behaviour of 'untreated' hyperplasia in 170 patients
18. Hyperplasia vs. neoplasia: Two tracks for the endometrium?
19. The cytodynamics of endometrial hyperplasia and carcinoma. A review
20. Predicting the outcome of endometrial hyperplasia by quantitative analysis of nuclear features using a linear discriminant function
21. Nuclear morphometry in the determination of the prognosis of marked atypical endometrial hyperplasia
22. Deoxyribonucleic acid content of the precursors of endometrial carcinoma
23. Endometrial intraepithelial neoplasia (EIN): Will it bring order to chaos
24. Uteri of women with endometrial carcinoma contain a histopathologic spectrum of monoclonal putative precancers, some with microsatellite instability
25. Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer
26. Use of computerized morphometric analyses of endometrial hyperplasias in the prediction of coexistent cancer
27. Architectural and nuclear morphometrical features together are more important prognosticators in endometrial hyperplasias than nuclear morphometrical features alone
28. Treatment of precursors of endometrial cancer
29. Invasive carcinoma in uteri resected for atypical endometrial hyperplasia
30. The prognostic and therapeutic implications of cytologic atypia in patients with endometrial hyperplasia
31. Endometrial hyperplasia and neoplasia. Cytologic screening with the endopap endometrial sampler
32. Transvaginal ultrasound, endometrial cytology sampled by Gynoscan and histology obtained by the Uterine Explora Curette compared to the histology of the uterine specimen
33. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding: A Nordic multicentre study
34. Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium
35. Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia
36. The biologic significance of cytologic atypia in progestin-treated endometrial hyperplasia
37. Hormonal receptors in endometrial neoplasias
38. Endometrial hyperplasia. A prospective randomized study of histopathology, tissue steroid receptors and plasma steroids after abrasio, with or without high dose gestagen treatment
39. Failure of down regulation of oestrogen receptors and progesterone receptors after medroxyprogesterone acetate administration for endometrial hyperplasias
40. Steroid receptor concentrations as a prognostic factor in atypical endometrial hyperplasia
41. Treatment of endometrial hyperplasia with levonorgesterol releasing intrauterine devices
42. Endometrial hyperplasia; Efficacy of a new treatment with a vaginal cream containing natural micronized progesterone
43. Danazol reverses endometrial hyperplasia to normal endometrium
44. Clinical effects of danazol on endometrial hyperplasia in menopausal and postmenopausal women
45. Danazol in the treatment of endometrial hyperplasia
46. Postmenopausal endometrial hyperplasia: Role of danazol therapy
47. Goserelin treatment in glandular hyperplasia
48. Low risk endometrial hyperplasia: Hysteroscopy and histologic evaluation after treatment with LH-RH analogue
49. Regression of endometrial hyperplasia after treatment with the gonadotrophin releasing hormone triptorelin: A prospective study
50. Atypical hyperplasia treatment with progestens and gonadotrophin releasing hormone analogues: Long term follow up
51. Treatment of benign uterine hemorrhage and simple endometrial hyperplasia by endometrial ablation
52. Hysteroscopic resection of endometrial hyperplasia
53. Not so benign endometrial hyperplasia: Endometrial cancer after endometrial ablation